- The diagnosis and management of women with LCIS should involve a multidisciplinary team who consider all relevant pathological, radiological and clinical data, and the individual patient’s risk profile and preferences.
- Patient involvement in the choice of management options is a key aspect of care. Women should receive adequate information regarding the implications of a diagnosis of LCIS, and the risks and benefits of the different management options.
- Management options for the majority of women with LCIS include surveillance, surgical excision, and risk-reducing medication.
- Surveillance includes annual clinical examination and bilateral imaging, subject to specialist clinical judgement (e.g. considering the age of the woman).
- If LCIS of the classic variant is found in isolation or as an incidental finding (on core needle or excision biopsy), with pathological-radiological concordance, then surveillance remains an option.
- If PLCIS is found on core needle biopsy, excision should be performed.
- If other sub-types of LCIS (such as classic LCIS with comedo-type necrosis and florid/bulky LCIS) are found on core needle biopsy, excision may be considered.
- There is no evidence to support the use of radiotherapy for LCIS in general, but adjuvant radiotherapy may be considered for women with PLCIS.
- Risk-reducing medication, including aromatase inhibitors or selective oestrogen receptor modulators, is an option for preventing invasive breast cancer, subject to an individual woman’s overall clinical profile.
Cancer Australia was established by the Australian Government in 2006 to benefit all Australians affected by cancer, and their families and carers. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across the continuum of care.
Freecall 1800 624 973
+61 2 9357 9400
Locked Bag 3, Strawberry Hills